Forest CEO: Aptalis a `Compelling Opportunity'

Jan. 8 (Bloomberg) -- Brent Saunders, chief executive officer of Forest Laboratories Inc., talks about the company's agreement to acquire Aptalis Pharma for $2.9 billion in cash. Aptalis is a closely held company whose shareholders include investment firm TPG Capital. Saunders speaks with Betty Liu on Bloomberg Television's "In the Loop." (Source: Bloomberg)
What's Driving the M&A Frenzy in Pharmaceuticals?
52:20 - Jefferies Analyst David Steinberg discusses mergers and acquisitions in the pharmaceutical industry. He speaks on “Bloomberg Markets.” (Source: Bloomberg)
  • Billion Dollar Jamie: Following Dimon's Path to Wealth
  • Greece’s Tsipras Wants Lenders to Be Realistic on Debt
  • Options Update: How to Play SPDR S&P Retail ETF